In vitro susceptibility of nonfermenting Gram-negative rods to meropenem-vaborbactam and delafloxacin
Meropenem-vaborbactam and delafloxacin activities were not assessed against spp. ( ), complex ( ) and ( ). A total of 106 , 57 and 100 were tested with gradient diffusion test of meropenem-vaborbactam, delafloxacin and comparators. Meropenem-vaborbactam MIC were 4 μg/ml for , 1 μg/ml for , 2 μg/ml...
Gespeichert in:
| Veröffentlicht in: | Future microbiology 2023-01, Vol.18 (2), p.117-126 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 126 |
|---|---|
| container_issue | 2 |
| container_start_page | 117 |
| container_title | Future microbiology |
| container_volume | 18 |
| creator | Farfour, Eric d'Epenoux, Louise Ruffier Muggeo, Anaëlle Alauzet, Corentine Crémet, Lise Moussalih, Sophie Roux, Antoine de Verdière, Sylvie C Bosphore, Amélie Corvec, Stéphane Guillard, Thomas Vasse, Marc |
| description | Meropenem-vaborbactam and delafloxacin activities were not assessed against
spp. (
),
complex (
) and
(
).
A total of 106
, 57
and 100
were tested with gradient diffusion test of meropenem-vaborbactam, delafloxacin and comparators.
Meropenem-vaborbactam MIC
were 4 μg/ml for
, 1 μg/ml for
, 2 μg/ml for
and
, and 32 μg/ml for
. Delafloxacin MIC
were 4 μg/ml for
, 0.25 μg/ml for
and
, 2 μg/ml for
, and 0.5 μg/m for
. meropenem-vaborbactam MICs were fourfold lower than meropenem for 28.3%
, 77.2%
, 53.8%
and 77.2%
.
Meropenem-vaborbactam and delafloxacin are
active against
and
. |
| doi_str_mv | 10.2217/fmb-2021-0278 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_03978223v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2771638170</sourcerecordid><originalsourceid>FETCH-LOGICAL-c327t-344420aa9837ecda475dd1b1e3542420aa824f849aadd607e4c6cad2b5b67ab13</originalsourceid><addsrcrecordid>eNo9kU1vFDEMhiMEoqXtkSvKEQ6h-drJzLGqSltpJS5wjpyJpwRNkiXJrui_7wxb9mTLfvRK9kPIR8G_SinM9RQdk1wKxqXp35BzYXTH-CDF21Mv1Bn5UOtvzje9GMR7cqY6I6Xi-pzgY6KH0EqmdV9H3LXgwhzaM80TTTlNWCKmFtITvS8QWcInaOGAtGRfacs0Ysk7TBjZAVwuDsYGkULy1OMM05z_whjSJXk3wVzx6rVekJ_f7n7cPrDt9_vH25stG5U0jSmtteQAQ68Mjh602XgvnEC10fLfppd66vUA4H3HDeqxG8FLt3GdASfUBflyzP0Fs92VEKE82wzBPtxs7TrjajD9cvphZT8f2V3Jf_ZYm41h-cA8Q8K8r1YaIzrVC8MXlB3RseRaC06nbMHtasEuFuxqwa4WFv7Ta_TeRfQn-v_b1QtpVoO8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2771638170</pqid></control><display><type>article</type><title>In vitro susceptibility of nonfermenting Gram-negative rods to meropenem-vaborbactam and delafloxacin</title><source>MEDLINE</source><source>PubMed Central</source><creator>Farfour, Eric ; d'Epenoux, Louise Ruffier ; Muggeo, Anaëlle ; Alauzet, Corentine ; Crémet, Lise ; Moussalih, Sophie ; Roux, Antoine ; de Verdière, Sylvie C ; Bosphore, Amélie ; Corvec, Stéphane ; Guillard, Thomas ; Vasse, Marc</creator><creatorcontrib>Farfour, Eric ; d'Epenoux, Louise Ruffier ; Muggeo, Anaëlle ; Alauzet, Corentine ; Crémet, Lise ; Moussalih, Sophie ; Roux, Antoine ; de Verdière, Sylvie C ; Bosphore, Amélie ; Corvec, Stéphane ; Guillard, Thomas ; Vasse, Marc</creatorcontrib><description>Meropenem-vaborbactam and delafloxacin activities were not assessed against
spp. (
),
complex (
) and
(
).
A total of 106
, 57
and 100
were tested with gradient diffusion test of meropenem-vaborbactam, delafloxacin and comparators.
Meropenem-vaborbactam MIC
were 4 μg/ml for
, 1 μg/ml for
, 2 μg/ml for
and
, and 32 μg/ml for
. Delafloxacin MIC
were 4 μg/ml for
, 0.25 μg/ml for
and
, 2 μg/ml for
, and 0.5 μg/m for
. meropenem-vaborbactam MICs were fourfold lower than meropenem for 28.3%
, 77.2%
, 53.8%
and 77.2%
.
Meropenem-vaborbactam and delafloxacin are
active against
and
.</description><identifier>ISSN: 1746-0913</identifier><identifier>EISSN: 1746-0921</identifier><identifier>DOI: 10.2217/fmb-2021-0278</identifier><identifier>PMID: 36722304</identifier><language>eng</language><publisher>England: Future Medicine</publisher><subject>Anti-Bacterial Agents - pharmacology ; Burkholderia cepacia complex ; Gram-Negative Bacteria ; Life Sciences ; Meropenem - pharmacology ; Microbial Sensitivity Tests ; Stenotrophomonas maltophilia</subject><ispartof>Future microbiology, 2023-01, Vol.18 (2), p.117-126</ispartof><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c327t-344420aa9837ecda475dd1b1e3542420aa824f849aadd607e4c6cad2b5b67ab13</citedby><cites>FETCH-LOGICAL-c327t-344420aa9837ecda475dd1b1e3542420aa824f849aadd607e4c6cad2b5b67ab13</cites><orcidid>0000-0003-3243-8018 ; 0000-0002-4241-3298 ; 0000-0002-9260-755X ; 0009-0009-0461-8848 ; 0000-0002-3795-0398</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36722304$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.univ-reims.fr/hal-03978223$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Farfour, Eric</creatorcontrib><creatorcontrib>d'Epenoux, Louise Ruffier</creatorcontrib><creatorcontrib>Muggeo, Anaëlle</creatorcontrib><creatorcontrib>Alauzet, Corentine</creatorcontrib><creatorcontrib>Crémet, Lise</creatorcontrib><creatorcontrib>Moussalih, Sophie</creatorcontrib><creatorcontrib>Roux, Antoine</creatorcontrib><creatorcontrib>de Verdière, Sylvie C</creatorcontrib><creatorcontrib>Bosphore, Amélie</creatorcontrib><creatorcontrib>Corvec, Stéphane</creatorcontrib><creatorcontrib>Guillard, Thomas</creatorcontrib><creatorcontrib>Vasse, Marc</creatorcontrib><title>In vitro susceptibility of nonfermenting Gram-negative rods to meropenem-vaborbactam and delafloxacin</title><title>Future microbiology</title><addtitle>Future Microbiol</addtitle><description>Meropenem-vaborbactam and delafloxacin activities were not assessed against
spp. (
),
complex (
) and
(
).
A total of 106
, 57
and 100
were tested with gradient diffusion test of meropenem-vaborbactam, delafloxacin and comparators.
Meropenem-vaborbactam MIC
were 4 μg/ml for
, 1 μg/ml for
, 2 μg/ml for
and
, and 32 μg/ml for
. Delafloxacin MIC
were 4 μg/ml for
, 0.25 μg/ml for
and
, 2 μg/ml for
, and 0.5 μg/m for
. meropenem-vaborbactam MICs were fourfold lower than meropenem for 28.3%
, 77.2%
, 53.8%
and 77.2%
.
Meropenem-vaborbactam and delafloxacin are
active against
and
.</description><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Burkholderia cepacia complex</subject><subject>Gram-Negative Bacteria</subject><subject>Life Sciences</subject><subject>Meropenem - pharmacology</subject><subject>Microbial Sensitivity Tests</subject><subject>Stenotrophomonas maltophilia</subject><issn>1746-0913</issn><issn>1746-0921</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kU1vFDEMhiMEoqXtkSvKEQ6h-drJzLGqSltpJS5wjpyJpwRNkiXJrui_7wxb9mTLfvRK9kPIR8G_SinM9RQdk1wKxqXp35BzYXTH-CDF21Mv1Bn5UOtvzje9GMR7cqY6I6Xi-pzgY6KH0EqmdV9H3LXgwhzaM80TTTlNWCKmFtITvS8QWcInaOGAtGRfacs0Ysk7TBjZAVwuDsYGkULy1OMM05z_whjSJXk3wVzx6rVekJ_f7n7cPrDt9_vH25stG5U0jSmtteQAQ68Mjh602XgvnEC10fLfppd66vUA4H3HDeqxG8FLt3GdASfUBflyzP0Fs92VEKE82wzBPtxs7TrjajD9cvphZT8f2V3Jf_ZYm41h-cA8Q8K8r1YaIzrVC8MXlB3RseRaC06nbMHtasEuFuxqwa4WFv7Ta_TeRfQn-v_b1QtpVoO8</recordid><startdate>202301</startdate><enddate>202301</enddate><creator>Farfour, Eric</creator><creator>d'Epenoux, Louise Ruffier</creator><creator>Muggeo, Anaëlle</creator><creator>Alauzet, Corentine</creator><creator>Crémet, Lise</creator><creator>Moussalih, Sophie</creator><creator>Roux, Antoine</creator><creator>de Verdière, Sylvie C</creator><creator>Bosphore, Amélie</creator><creator>Corvec, Stéphane</creator><creator>Guillard, Thomas</creator><creator>Vasse, Marc</creator><general>Future Medicine</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0003-3243-8018</orcidid><orcidid>https://orcid.org/0000-0002-4241-3298</orcidid><orcidid>https://orcid.org/0000-0002-9260-755X</orcidid><orcidid>https://orcid.org/0009-0009-0461-8848</orcidid><orcidid>https://orcid.org/0000-0002-3795-0398</orcidid></search><sort><creationdate>202301</creationdate><title>In vitro susceptibility of nonfermenting Gram-negative rods to meropenem-vaborbactam and delafloxacin</title><author>Farfour, Eric ; d'Epenoux, Louise Ruffier ; Muggeo, Anaëlle ; Alauzet, Corentine ; Crémet, Lise ; Moussalih, Sophie ; Roux, Antoine ; de Verdière, Sylvie C ; Bosphore, Amélie ; Corvec, Stéphane ; Guillard, Thomas ; Vasse, Marc</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c327t-344420aa9837ecda475dd1b1e3542420aa824f849aadd607e4c6cad2b5b67ab13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Burkholderia cepacia complex</topic><topic>Gram-Negative Bacteria</topic><topic>Life Sciences</topic><topic>Meropenem - pharmacology</topic><topic>Microbial Sensitivity Tests</topic><topic>Stenotrophomonas maltophilia</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Farfour, Eric</creatorcontrib><creatorcontrib>d'Epenoux, Louise Ruffier</creatorcontrib><creatorcontrib>Muggeo, Anaëlle</creatorcontrib><creatorcontrib>Alauzet, Corentine</creatorcontrib><creatorcontrib>Crémet, Lise</creatorcontrib><creatorcontrib>Moussalih, Sophie</creatorcontrib><creatorcontrib>Roux, Antoine</creatorcontrib><creatorcontrib>de Verdière, Sylvie C</creatorcontrib><creatorcontrib>Bosphore, Amélie</creatorcontrib><creatorcontrib>Corvec, Stéphane</creatorcontrib><creatorcontrib>Guillard, Thomas</creatorcontrib><creatorcontrib>Vasse, Marc</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Future microbiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Farfour, Eric</au><au>d'Epenoux, Louise Ruffier</au><au>Muggeo, Anaëlle</au><au>Alauzet, Corentine</au><au>Crémet, Lise</au><au>Moussalih, Sophie</au><au>Roux, Antoine</au><au>de Verdière, Sylvie C</au><au>Bosphore, Amélie</au><au>Corvec, Stéphane</au><au>Guillard, Thomas</au><au>Vasse, Marc</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In vitro susceptibility of nonfermenting Gram-negative rods to meropenem-vaborbactam and delafloxacin</atitle><jtitle>Future microbiology</jtitle><addtitle>Future Microbiol</addtitle><date>2023-01</date><risdate>2023</risdate><volume>18</volume><issue>2</issue><spage>117</spage><epage>126</epage><pages>117-126</pages><issn>1746-0913</issn><eissn>1746-0921</eissn><abstract>Meropenem-vaborbactam and delafloxacin activities were not assessed against
spp. (
),
complex (
) and
(
).
A total of 106
, 57
and 100
were tested with gradient diffusion test of meropenem-vaborbactam, delafloxacin and comparators.
Meropenem-vaborbactam MIC
were 4 μg/ml for
, 1 μg/ml for
, 2 μg/ml for
and
, and 32 μg/ml for
. Delafloxacin MIC
were 4 μg/ml for
, 0.25 μg/ml for
and
, 2 μg/ml for
, and 0.5 μg/m for
. meropenem-vaborbactam MICs were fourfold lower than meropenem for 28.3%
, 77.2%
, 53.8%
and 77.2%
.
Meropenem-vaborbactam and delafloxacin are
active against
and
.</abstract><cop>England</cop><pub>Future Medicine</pub><pmid>36722304</pmid><doi>10.2217/fmb-2021-0278</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0003-3243-8018</orcidid><orcidid>https://orcid.org/0000-0002-4241-3298</orcidid><orcidid>https://orcid.org/0000-0002-9260-755X</orcidid><orcidid>https://orcid.org/0009-0009-0461-8848</orcidid><orcidid>https://orcid.org/0000-0002-3795-0398</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1746-0913 |
| ispartof | Future microbiology, 2023-01, Vol.18 (2), p.117-126 |
| issn | 1746-0913 1746-0921 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_03978223v1 |
| source | MEDLINE; PubMed Central |
| subjects | Anti-Bacterial Agents - pharmacology Burkholderia cepacia complex Gram-Negative Bacteria Life Sciences Meropenem - pharmacology Microbial Sensitivity Tests Stenotrophomonas maltophilia |
| title | In vitro susceptibility of nonfermenting Gram-negative rods to meropenem-vaborbactam and delafloxacin |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T03%3A42%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20vitro%20susceptibility%20of%20nonfermenting%20Gram-negative%20rods%20to%20meropenem-vaborbactam%20and%20delafloxacin&rft.jtitle=Future%20microbiology&rft.au=Farfour,%20Eric&rft.date=2023-01&rft.volume=18&rft.issue=2&rft.spage=117&rft.epage=126&rft.pages=117-126&rft.issn=1746-0913&rft.eissn=1746-0921&rft_id=info:doi/10.2217/fmb-2021-0278&rft_dat=%3Cproquest_hal_p%3E2771638170%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2771638170&rft_id=info:pmid/36722304&rfr_iscdi=true |